meRfi®-GM
CD152 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4))
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
CTLA-4 is upregulated upon T-cell activation
CTLA-4 interacts with CD80 and CD86
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is not expressed by resting naive T cells, but becomes detectable 2 days after activation
CTLA-4 competes with the CD28 receptor for binding to B7 ligands
CTLA-4 carries out its effects through other cells (cell-extrinsic models)
Engagement of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) by the ligands B7-1 and B7-2 imparts a negative signal to T-cells and results in alteration of T-cell activit…
References (Sources)
- Ipilimumab in Prostate Cancer
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell respons
- The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulationReview
- The soluble isoform of CTLA-4 as a regulator of T-cell responses
- Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA4 antibodiesReview
- VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy